Erufosine is an inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It suppresses the activity of breast cancer cell lines MCF-7 and MDA-MB 231 with an IC50 of 40.95/40.8 µM, respectively. Erufosine reduces phosphorylation of PI3K(p85), Akt (PKB), and cRaf, making it applicable in research on breast cancer and myeloid leukemia.
Molecular Weight:
503.74
CAS Number:
[202867-33-2]
Formula:
C28H58NO4P
Target:
Akt|||Ras|||Raf|||PI3K|||p38 MAPK
T211021
* VAT and and shipping costs not included. Errors and price changes excepted
